What tumor-related factors help in deciding between BRAF/MEKi vs ICI in stage IV BRAF mutant melanoma patients?  

Any patient who has a contraindication to ICI (autoimmune disease, transplant, etc...), I start with BRAF inhibitors, unless the patient is eligible for a clinical trial. Otherwise, I start with ICI, given the latest results of ECOG EA6134. Whether I choose combo with ipi and single agent PD1 inhib...